Abstract
To compare management and outcomes of SLE patients treated in community clinics (Cc) with those treated in specialty clinic (Sc) within 10 years after SLE diagnosis. A single-center, matched cohort study design was used. We identified 54 SLE patients who were referred to a Sc from Cc within 5 years of SLE diagnosis, and 101 inception SLE patients who followed in a Sc. Patients in Cc were matched 1:2 based on gender, decade of SLE diagnosis, and age at diagnosis within 3 years with Sc patients. Disease characteristics, damage accumulation, death, cardiovascular (CVS) risk factors, and events were compared at 5 and 10 years of disease. Regression analyses taking into account the paired data were conducted. At 5 years of disease, patients referred from Cc had less cumulative ACR criteria, but more active disease. They were on higher doses of glucocorticoids (GCS) but less antimalarial treatment. At 10 years of disease and follow-up entirely in Sc, Sc patients had less disease activity. They had lower cumulative GCS doses. They had less hypertension and osteoporosis but more hypercholesterolemia than Cc patients. No statistically significant difference in damage accrual, CVS events, and death were detected. Regression analysis confirmed an association between being inception Sc patients and less active disease at 10 years. Lupus patients should be under the care of a lupus specialist early in their disease course for better control of their disease activity and to minimize use of GCS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Swaak AJG, van den Brink HG, Smeenk RJ, Manger K, Kalden JR, Tosi S et al (1999) Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology (Oxford, England) 38:953–958
Urowitz MB, Kagal A, Rahman P, Gladman DD (2002) Role of specialty care in the management of patients with systemic lupus erythematosus. J Rheumatol 29:1207–1210
Urowitz MB, Gladman DD, Tom BD, Ibanez D, Farewell VT (2008) Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 35:2152–2158
Urowitz MB, Gladman DD (2005) Contributions of observational cohort studies in systemic lupus erythematosus: the university of toronto lupus clinic experience. Rheum Dis Clin N Am 31:211–221
Touma Z, Gladman DD, Urowitz MB (2013) Clinical measures, metrics and indices. In: Dubois lupus erythematosus and related syndromes, 8th edn. Elsevier Saunders, Publisher, pp 563–581
Zink A, Fischer-Betz R, Thiele K, Listing J, Huscher D, Gromnica-Ihle E et al (2004) Health care and burden of illness in systemic lupus erythematosus compared to rheumatoid arthritis: results from the National Database of the German Collaborative Arthritis Centres. Lupus 13:529–536
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291
Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369
Swaak AJ, Nossent JC, Bronsveld W, Van Rooyen A, Nieuwenhuys EJ, Theuns L et al (1989) Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 48:447–454
Ruiz-Irastorza G, Danza A, Khamashta M (2012) Glucocorticoid use and abuse in SLE. Rheumatology (Oxford, England) 51(7):1145–1153
Urowitz M, Gladman D, Bruce I (2000) Atherosclerosis and systemic lupus erythematosus. Curr Rheumatol Rep 2(1):19–23
Bruce IN, Urowitz MB, Gladman DD, Hallett DC (1999) Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 26:2137–2143
Molina MJ, Mayor AM, Franco AE, Morell CA, Lopez MA, Vila LM (2008) Utilization of health services and prescription patterns among lupus patients followed by primary care physicians and rheumatologists in Puerto Rico. Ethn Dis 18(Suppl 2):S2–205-10
Curtis JR, Westfall AO, Allison JJ, Becker A, Casebeer L, Freeman A et al (2005) Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 52:2485–2494
Yood RA, Harrold LR, Fish L, Cernieux J, Emani S, Conboy E et al (2001) Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Arch Intern Med 161:1322–1327
Schmajuk G, Yazdany J, Trupin L, Yelin E (2010) Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62:386–392
Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB (2000) Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 27:2142–2145
Fessler BJ, Alarcon GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW et al (2005) Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52:1473–1480
Molad Y, Gorshtein A, Wysenbeek AJ, Guedj D, Majadla R, Weinberger A et al (2002) Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 11:356–361
Ho KT, Ahn CW, Alarcon GS, Baethge BA, Tan FK, Roseman J et al (2005) Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford, England) 44:1303–1307
Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN (1999) The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 26:325–330
Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N (2001) Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 28:102–108
Acknowledgments
The Lupus research program is supported in part by Lou and Marissa Rocca, and the Lupus Foundation of Ontario
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Rights and permissions
About this article
Cite this article
Aljohani, R., Gladman, D.D., Su, J. et al. Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics. Clin Rheumatol 36, 1773–1778 (2017). https://doi.org/10.1007/s10067-017-3713-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-017-3713-7